Flutoprazepam CAS No. 25967-29-7

Uses

• Primary Uses:

  • Severe insomnia

  • Anxiety disorders

  • Historically used for stomach ulcers due to muscle relaxant properties

• Research Use: Primarily a research chemical or designer drug

• Regional Use: Mainly used in Japan under the brand name Restas

Legal / Status

• Regulation: Not approved for medical use in most countries, including the United States and the European Union

• Controlled Substance: Classified as a controlled substance in many countries

• International Convention: Not listed under the 1971 Convention on Psychotropic Substances

Side Effects

• Common Side Effects:

  • Drowsiness/sedation

  • Daytime sleepiness

  • Dizziness or lightheadedness

  • Cognitive impairment (memory problems, difficulty concentrating)

  • Muscle weakness

• Serious Side Effects:

  • Risk of dependence and addiction with long-term use

  • Paradoxical reactions (agitation, anxiety, aggression)

  • Complex sleep behaviors (e.g., sleep-driving, sleep-walking)

Risks and Dangers

• Dependence and Addiction: High potential for physical and psychological dependence

• Tolerance: Users may need to increase the dose over time

• Withdrawal Syndrome: Severe and potentially life-threatening symptoms

• Overdose Risk: Increased when mixed with other CNS depressants (alcohol, opioids)

• Cognitive Impairment: Significant drowsiness, confusion, memory problems

• Lack of Quality Control: Unregulated status leads to risks of accidental overdose

Physical and Chemical Properties

• Density: 1.37 g/cm³

• Boiling Point: 539.3°C

• Flash Point: 279.9°C

• Solubility:

  • DMF: 30 mg/ml

  • DMF:PBS (pH 7.2) (1:1): 0.5 mg/ml

  • DMSO: 25 mg/ml

  • Ethanol: 1 mg/ml

Structure

• Chemical Family: 1,4-Benzodiazepine

• Substitutions: Chloro (Cl) and fluoro (F) atoms

• Core Scaffold: Benzodiazepinone with a phenyl substituent at the 5-position

• Structure: 7-Chloro-1-(cyclopropylmethyl)-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one

Pharmacology

• Mechanism of Action: Acts as a GABA-A receptor positive allosteric modulator, enhancing the effect of GABA in the CNS.

• Primary Effects: Sedative, hypnotic, anxiolytic, anticonvulsant, muscle relaxant

• Potency: Approximately four times more potent than diazepam (Valium) by weight

• Duration of Action: Long-lasting due to the active metabolite N-desalkylflurazepam

• Metabolite: N-desalkylflurazepam (half-life: 40-250 hours)

Safety and Handling

• Storage: Store according to product insert instructions

• Handling: Follow usual precautionary measures for handling chemicals

• Protective Equipment:

  • Breathing equipment: Not required

  • Hand protection: Use impermeable and resistant gloves

  • Eye protection: Not required

Ecological Information

• Toxicity: No specific data available

• Persistence and Degradability: No specific data available

• Bioaccumulative Potential: No specific data available

• Mobility in Soil: No specific data available

• Water Hazard Class: 1 (slightly hazardous for water)

Disposal

• Waste Treatment: Smaller quantities can be disposed of with household waste

• Uncleaned Packagings: Dispose according to official regulations

Product Documents

• Safety Data Sheet (SDS)
• Certificate of Analysis
• Product Brochure
• Technical Data Sheet